Related Experiment Video
Updated: Jun 18, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
ADP receptor P2Y(13) induce apoptosis in pancreatic beta-cells
Chanyuan Tan1, Albert Salehi, Siv Svensson
1Department of Cardiology, Lund University, 22185 Lund, Sweden.
Abstract:
Pancreatic beta-cell loss represents a key factor in the pathogenesis of diabetes. Since the influence of purinergic signaling in beta-cell apoptosis has not been much investigated, we examined the role of the ADP receptor P2Y(13) using the pancreatic insulinoma-cell line MIN6c4 as a model system. Real time-PCR revealed high expression of the ADP receptors P2Y(1) and P2Y(13). Adding the ADP analogue, 2MeSADP, to MIN6c4 cells induced calcium influx/mobilization and inhibition of cAMP production by activation of P2Y(1) and P2Y(13), respectively. 2MeSADP reduced cell proliferation and increased Caspase-3 activity; both these effects could be fully reversed by the P2Y(13) receptor antagonist MRS2211. We further discovered that blocking the P2Y(13) receptor results in enhanced ERK1/2, Akt/PKB and CREB phosphorylation mechanisms involved in beta-cell survival. These results indicate that P2Y(13) is a proapoptotic receptor in beta-cells as the P2Y(13) receptor antagonist MRS2211 is able to protect the cells from ADP induced apoptosis.
Insights
Pancreatic beta-cell loss contributes to diabetes. This study reveals the ADP receptor P2Y(13) promotes beta-cell apoptosis, and its antagonist, MRS2211, protects these cells, offering a potential therapeutic target.
Area of Science:
- Cell Biology
- Endocrinology
- Pharmacology
Background:
- Pancreatic beta-cell loss is central to diabetes pathogenesis.
- Purinergic signaling's role in beta-cell apoptosis is under-explored.
Purpose of the Study:
- Investigate the function of the ADP receptor P2Y(13) in beta-cell apoptosis.
- Determine the therapeutic potential of P2Y(13) antagonists.
Main Methods:
- Utilized the MIN6c4 pancreatic beta-cell line.
- Assessed gene expression via real-time PCR.
- Measured calcium influx, cAMP production, cell proliferation, and Caspase-3 activity.
- Examined ERK1/2, Akt/PKB, and CREB phosphorylation.
Main Results:
- MIN6c4 cells express high levels of ADP receptors P2Y(1) and P2Y(13).
- ADP analogue 2MeSADP activated P2Y(1) and P2Y(13), inhibiting cAMP and reducing proliferation.
- 2MeSADP increased Caspase-3 activity, indicating apoptosis.
- The P2Y(13) antagonist MRS2211 reversed these pro-apoptotic effects and enhanced survival signaling pathways.
Conclusions:
- P2Y(13) acts as a pro-apoptotic receptor in pancreatic beta-cells.
- Blocking P2Y(13) with MRS2211 protects beta-cells from ADP-induced apoptosis.
- Targeting P2Y(13) may offer a novel strategy for managing diabetes.
More Related Videos
Related Concept Videos
Acute Pancreatitis II: Pathophysiology
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Cell Specific Gene Expression
Insulin Secretory Vesicles
The Extrinsic Apoptotic Pathway
Type I Diabetes II: Pathophysiology

